Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

• A histologically or cytologically confirmed diagnosis of Stage IV squamous ornon-squamous NSCLC

• Has not received prior systemic treatment for metastatic NSCLC

• Has measurable disease based on RECIST 1.1, as determined by the local siteassessment

• Has a life expectancy of at least 3 months

• Males: Use contraception unless confirmed to be azoospermic; Females: Women ofchildbearing potential use highly effective contraceptive method

Exclusion Criteria:

• Known additional malignancy that is progressing or has required active treatmentwithin the past 3 years

• Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

• Severe hypersensitivity to MK-7684, MK-7684A, pembrolizumab, chemotherapycomponents, and/or any of its excipients

• Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (indosing exceeding 10 mg daily of prednisone equivalent) or any other form ofimmunosuppressive therapy within 7 days before the first dose of study medication

• Active autoimmune disease that has required systemic treatment in past 2 years,except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid)

• History of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease

• Has an active infection requiring systemic therapy

• Has a known history of human immunodeficiency virus (HIV), Hepatitis B or/andHepatitis C virus

• Received prior systemic anticancer therapy for metastatic disease

• Received a live or live attenuated vaccine within 30 days before the first dose ofstudy intervention. Administration of killed vaccines are allowed

• History of allogeneic tissue/solid organ transplant

• Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 g/day, for a 5-day period (8-day periodfor long-acting agents, such as piroxicam)

• Is unable or unwilling to take folic acid or vitamin B12 supplementation

• Currently participating in or has participated in a study of an investigationalagent or has used an investigational device within 4 weeks before the first dose ofstudy intervention